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DNA methylation profiling identifies novel
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Abstract
Background: Chronic hepatitis B infection is characterized by hepatic immune and inflammatory response with
considerable variation in the rates of progression to cirrhosis. Genetic variants and environmental cues influence
predisposition to the development of chronic liver disease; however, it remains unknown if aberrant DNA methylation
is associated with fibrosis progression in chronic hepatitis B.
Results: To identify epigenetic marks associated with inflammatory and fibrotic processes of the hepatitis B-induced
chronic liver disease, we carried out hepatic genome-wide methylation profiling using Illumina Infinium BeadArrays
comparing mild and severe fibrotic disease in a discovery cohort of 29 patients. We obtained 310 differentially
methylated regions and selected four loci comprising three genes from the top differentially methylated regions:
hypermethylation of HOXA2 and HDAC4 along with hypomethylation of PPP1R18 were significantly linked to
severe fibrosis. We replicated the prominent methylation marks in an independent cohort of 102 patients by
bisulfite modification and pyrosequencing. The timing and causal relationship of epigenetic modifications with
disease severity was further investigated using a cohort of patients with serial biopsies.
Conclusions: Our findings suggest a linkage of widespread epigenetic dysregulation with disease progression in
chronic hepatitis B infection. CpG methylation at novel genes sheds light on new molecular pathways, which can
be potentially exploited as a biomarker or targeted to attenuate inflammation and fibrosis.
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Background
Hepatitis B is the one of the leading causes of chronic liver
disease; 350 million people are chronically infected by the
hepatitis B virus worldwide [1]. It has been estimated that
hepatitis B infection is responsible for more than 500,000
deaths annually and is the 15th most common cause of
death globally [2, 3]. Chronic hepatitis B infection is char-
acterized by immune-mediated liver damage leading to
necroinflammation and accumulation of fibrotic tissue.
Persistent viral replication and repetitive hepatic injury
may ultimately evolve into cirrhosis, together with sub-
stantially increased risk of adverse clinical outcomes such
as liver failure, portal hypertension and hepatocellular
carcinoma [4].
Hepatic inflammation and fibrotic processes comprise
complex cellular and molecular interactions. Progression
from chronic hepatic inflammation to the fibrotic/cir-
rhotic stage is underpinned by numerous core pathways,
observed in other fibrotic diseases, as well as tissue- or
injury-specific pathways that are only activated in particu-
lar conditions [5, 6]. Depending on the activity of such
mechanisms, progression to fibrosis varies significantly
among hepatitis B-infected individuals, as in other liver
disorders [4]. To date, several studies have linked genetic
and environmental factors to the propensity towards
hepatic fibrosis progression. Genetic polymorphisms
* Correspondence: mzeybel@ku.edu.tr
†Equal contributors
1Institute of Cellular Medicine, Newcastle University, Newcastle upon Tyne,
UK
2School of Medicine, Koç University Hospital, Koç University, 4th floor-
M-4220. Davutpaşa Caddesi no: 4, 34010 Istanbul, Turkey
Full list of author information is available at the end of the article
© 2016 Zeybel et al. Open Access This article is distributed under the terms of the Creative Commons Attribution 4.0
International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and
reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to
the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver
(http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
Zeybel et al. Clinical Epigenetics  (2016) 8:48 
DOI 10.1186/s13148-016-0218-1
(patatin-like phospholipase domain-containing protein
3 (PNPLA3), transmembrane 6 superfamily member 2
(TM6SF2), seven-gene signatures) have been particu-
larly associated with the susceptibility of advanced liver
disease in non-alcoholic fatty liver disease and chronic
hepatitis C infection [7–11]. While the influence of
genetic variants in hepatitis B-associated chronic liver
disease is less clearly established, a recent study indicated
that the rs12979860 polymorphism of interferon-λ is con-
sistently linked to hepatic fibrosis in liver diseases includ-
ing chronic hepatitis B infection [12].
DNA methylation is the addition of methyl group to a
fifth carbon of cytosine residues within a CG dinucleo-
tide, frequently referred to as cytosine-guanine dinucleo-
tide (CpG). This type of DNA methylation is an essential
component of epigenetic machinery that regulates the
transcriptional state, alongside histone modifications and
microRNAs. As a transcriptional regulator, DNA methy-
lation has a considerable impact on the development of
common diseases and cancer [13, 14]. Epigenetic mecha-
nisms are dynamically regulated throughout the lifetime
and act as an interphase between genetic background
and environmental cues. CpG methylation-mediated
transcriptional control and epigenetic dysregulation have
also been implicated as an important contributing factor
in liver diseases including non-alcoholic fatty liver disease
and alcoholic liver disease [15, 16]. However, it is not
known whether epigenetic signatures influence progres-
sion of hepatitis B-related liver disease. We hypothesized
that epigenetic signatures can be associated with liver dis-
ease progression, and in order to define epigenetic pat-
terns in early and advanced stages of inflammation and
fibrosis, we performed an hepatic DNA methylome ana-
lysis using liver specimens of chronic hepatitis B patients.
Alterations in DNA methylome were further investigated
and replicated in the independent cohort and in the co-
hort of patients with sequential biopsies.
Results and discussion
To identify DNA methylation alterations in hepatitis B-
induced liver disease, we conducted an epigenome-wide
mapping using Infinium HumanMethylation450 Bead-
Chip platform. Our discovery cohort included 29 hepa-
titis B virus (HBV)-infected patients allocated into either
a mild fibrosis group (13 patients, fibrosis stage ≤2) or
severe fibrosis group (16 patients, fibrosis stage ≥3) (for
study design, please see Additional file 1: Figure S1). To
minimize the effect of the immune stage of the disease,
only hepatitis e antigen-negative patients were included
into the discovery cohort. The clinical characteristics,
histological activity and staging of the discovery cohort
are provided in Table 1. Baseline demographics revealed
no significant differences between mild and severe
groups. The mean CpG sites detected across the study
group was 462,891. We identified a total of 310 differen-
tially methylated regions between the mild and severe
groups; 109 of them were significantly hypermethylated,
and 201 were hypomethylated in the advanced group.
Top-ranked 40 differentially methylated regions are sum-
marized in Additional file 2: Table S1; which includes
HLA-DQA1 (major histocompatibility complex, class II,
DQ alpha 1), TMEM57 (transmembrane protein 57) and
HDAC4 (histone deacetylase 4). Differentially methylated
position analysis revealed that 18,234 probes showed sig-
nificant methylation differences between the two groups;
11,475 loci were associated with higher amounts of
methylation and 6759 loci were hypomethylated in the






n = 16 n = 13
Gender—malea 9 (56.2) 8 (61.5) ns
Age (years)a 48.2 ± 14.7 54.2 ± 11.6 ns
Hbe Ag positivea – (0) – (0) ns
Anti Hbe Ab positivea 16 (100) 13 (100) –
HBV DNA (log IU/mL)b 6.2 ± 5.8 8.5 ± 4.7 ns
Serum ALT (IU/L)b 56.5 ± 35.6 106.2 ± 87.1 ns
Serum AST (IU/L)b 41.7 ± 29.1 75.1 ± 56.1 0.01
White blood cell count
(×109/L)b
6.2 ± 1.2 5.6 ± 1.4 ns
Platelet count (×109/L)b 218.9 ± 52.1 177.9 ± 64.54 ns
Haemoglobin (g/L)b 13.8 ± 0.9 13.6 ± 1.6 ns
Albumin (g/L)b 4.4 ± 0.3 4.4 ± 0.4 ns
Prothrombin time (s)b 11.8 ± 0.8 12.1 ± 0.9 ns
Direct bilirubin (mg/dL)b 0.31 ± 0.1 0.37 ± 0.1 ns
Modified histologic activity
indexa
0–4 9 (56.25) 2 (15.3)
5–9 7 (43.75) 9 (69.23)
10–14 – 2 (15.3)
15–18 – –
Fibrosisa
0 9 (56.25) –
1 2 (12.5) –
2 5 (31.25) –
3 – 4 (30.7)
4 – 3 (23.0)
5 – 4 (30.7)
6 – 2 (15.3)
a,bData are shown as number and percentage (a) or mean and standard
deviation (b). The histologic activity index is a sum of portal inflammation,
confluent necrosis, focal lytic necrosis and periportal or periseptal interface
hepatitis scores which was expressed on a scale of 18. Fibrosis stage was
assessed on a scale of 0 to 6
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severe fibrosis group. The top 20 hypermethylated and
hypomethylated probes associated with disease severity are
provided in Additional file 3: Table S2 and Additional file 4:
Table S3. Figure 1 illustrates the main characteristics of the
breakdown of the CpG sites in relation to transcripts and
clusters of CpG sites (CpG islands). Hypomethylated CpG
sites in advanced disease were more frequently located
within or close proximity to CpG islands (31.3 vs 14.7 %)
and transcription start sites (29.3 vs 16.5 %).
Using bioinformatics assessment and pathway ana-
lysis, we identified two individual CpG sites which
were strongly associated with the disease progression:
cg13985518 (chr7:27143788, HOXA2 (homeobox A2),
CpG site located within 1500 base pairs of transcription
start site) and cg20690667 (chr6:30652228, PPP1R18 (pro-
tein phosphatase 1, regulator subunit 18), CpG site posi-
tioned within the gene body-1st exon). Further analysis on
differentially methylated regions showed that the HDAC4
gene body (chr2:240241154-240241218) is markedly hyper-
methylated in the severe group (P = 0.002). We further de-
signed pyrosequencing assays to test relevant or nearby
CpGs in HOXA2 and PPP1R18 genes and two CpGs in
the HDAC4 gene (chr2:240241209-CpG1 and 240241218-
CpG2, CpG sites are located in the gene body) by locus-
Fig. 1 a The pie chart shows differentially methylated probes in advanced versus mild fibrosis according to UCSC classification of CpG islands:
Island (CpG island), N. Shore and shelf (2-kb upstream of CpG islands and 2–4-kb upstream of CpG islands, flanking regions of shores), Open Sea,
S. Shore and shelf (2-kb downstream of CpG islands and flanking regions of shores). b Pie chart illustrates probes with methylation differences in
advanced versus mild according to functional regions: TSS200 and 1500 (200- and 1500-bp upstream of transcription start sites; annotated promoters),
5′UTR (5′ untranslated region), 1st Exon, Gene body, 3′UTR (3′ untranslated region). c Pie charts show hypomethylated probes in advanced inflammation
and fibrosis in comparison to mild fibrosis according to CpG clusters and functional regions. d Pie charts show hypermethylated probes in advanced
inflammation and fibrosis in comparison to mild fibrosis according to CpG clusters and functional regions. e–f Number and percentages of differentially
methylated probes
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specific DNA methylation analysis in the discovery cohort
(Fig. 2). Validation plots of primer sets are provided in
Additional file 5: Figure S2; the assays gave satisfactory re-
sults with r2 values over 0.95. We obtained similar DNA
methylation changes in HOXA2, PPP1R18 and HDAC4
genes (P values are 0.01, 0.01, 0.01 and 0.007, respectively)
as shown in Fig. 2. We also examined the protein levels
and localisation of HDAC4 in liver sections of hepatitis
B patients (Additional file 6: Figure S3). In the early
stages of inflammation and fibrosis, HDAC expression
was barely detectable in hepatocytes. HDAC4 positivity
was detected in myofibroblast-like cells, inflammatory
and biliary cells and hepatocytes adjacent to fibrosis
tracts in hepatitis B-induced cirrhosis (Additional file 6:
Figure S3).
We assessed the association of the newly discovered
DNA methylation changes in a larger cohort comprising
102 retrospectively recruited patients; in this cohort, 70
patients had mild (Ishak fibrosis stage 0-2) and 32 had se-
vere liver disease (Ishak fibrosis stage 3-6) due to chronic
hepatitis B infection. The patient characteristics according
to the fibrosis stage are shown in Table 2. Similarly, epi-
genetic examination was conducted using bisulfite modifi-
cation and pyrosequencing analysis. As illustrated in
Fig. 3, marked increase in HOXA2 DNA methylation
was demonstrated in the severe fibrosis group versus
the mild group (chr7:27143806, mean ± SE, 48.8 ± 2.0 vs
58.9 ± 2.5); conversely, significantly lower CpG methyla-
tion values were detected in advanced disease at the
PPP1R18 gene (chr6:30652228, mean ± SE, 34.1 ± 2.9 vs
24.5 ± 3.7). Elevated methylation levels in the HDAC4
gene body associated with progression of necroinflamma-
tion and fibrosis were confirmed in previously described
two loci (chr2:240241209, 17.5 ± 2.0 vs 25.89 ± 3.27 and
chr2:240241218, 18.7 ± 5.0 vs 35.6 ± 5.2).
Given the dynamic status of epigenetic modifications,
we next considered whether methylation variations in
the observed regions developed as a consequence of dis-
ease progression. To assess the causality and association
of epigenetic imprints, we performed methylation ana-
lysis in a cohort of patients with sequential biopsies. Pa-
tients were included either into the progressor group
(fibrosis stage was increased between two biopsies) or
into the non-progressor group (fibrosis stage remained
stable) (Additional file 7: Table S4). The comparison of
DNA methylation analysis in two groups demonstrated
that methylation signatures were not different at initial bi-
opsies (Fig. 4). We further examined the methylation
changes using initial and follow-up biopsies. This analysis
indicated that only HOXA2 methylation was increased in
the progression of hepatitis B-induced chronic liver dis-
ease (Additional file 8: Figure S4).
Fig. 2 Plots were demonstrated as the correlation between the CpG methylation and severity of the liver disease. The analysis compares the
hepatic DNA methylation level in the Ishak fibrosis stages of F0-2 with F3-6. Horizontal bars represent the means and 95 % confidence interval.
Using bisulfite modification and pyrosequencing, hepatic cytosine methylation at four loci was assessed. Changes in HDAC4 (a, b), HOXA2 (c) and
PPP1R18 (d) CpG methylation are associated with severe inflammation and fibrosis in the discovery cohort
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To our knowledge, this is the first epigenome-wide
methylation study comparing mild and severe hepatitis B-
related liver disease. Analysis of genome-wide differentially
methylated CpG sites and regions in the discovery cohort
revealed widespread alterations in the DNA methylome in
the progression of chronic liver disease; 310 differentially
methylated regions (109 hypermethylated CpG sites and
201 hypomethylated CpG sites) were linked to severe hep-
atic inflammation and fibrosis. We identified hypermethy-
lation of three loci in HDAC4 and HOXA2 genes and a less
methylated CpG site in the PPP1R18 gene in HBV-
associated advanced liver fibrosis. Epigenetic differences at
four newly identified CpG sites have not previously been
linked with chronic liver disease. Observed differences
were also confirmed by bisulfite conversion and pyrose-
quencing in an independent patient cohort. Prior studies
on epigenetics of chronic liver disease and hepatocellular
carcinoma have noted the importance of DNA methylation
in disease development [17, 18]. Furthermore, recent re-
search also suggests that hepatitis B infection induces
genome-wide methylation changes in hepatocytes [19, 20].
The current study, while supporting previous findings,
also expands our understanding of methylome alter-
ations in histologically proven hepatitis B-induced in-
flammation and fibrosis.
HDAC4 is a member of class II histone deacetylases and
is located in both nuclear and cytoplasmic compartments
of cells. Methylation differences in the HDAC4 gene have a
particular importance, since HDAC4 executes deacetyla-
tion of histone proteins and changes chromatin configur-
ation, which results in transcriptional repression. Given
that CpG methylation in the gene body is frequently ob-
served in transcriptionally active genes, higher expression
of HDAC4 might be expected in the severe liver disease
group [21]. Indeed, we observed the abundance of HDAC4
expression in fibrosis tracts of hepatitis B-cirrhosis; con-
versely, it was significantly less expressed in mild disease. It
is likely that the presence of CpG methylation within the
HDAC4 gene may lead to the removal of acetyl groups
from histone tails, further repressing transcription. The re-
sults of this study are consistent with recent in vitro studies
indicating that HDAC4 plays a key role in myofibroblastic
differentiation and fibrogenesis [22]. Furthermore, there
is growing evidence that pharmacological inhibition of
HDACs by trichostatin A, largazole or valproic acid
suppresses fibrogenesis in primary hepatic stellate cells
and animal models of liver fibrosis [23–25]. Crosstalk
between DNA methylation and histone modifications
has been studied extensively [26]. This study raises the
possibility that a multifaceted interplay of epigenetic
mechanisms may control the progression of chronic liver
disease. A potential complementary mechanism for regula-
tion of inflammation and matrix remodelling may be the
interaction of genetic variations and epigenetic machineries,
e.g. the presence of single nucleotide polymorphisms at the
HDAC gene may be a promising tool to predict treatment
response in chronic hepatitis C infection [27].
HOXA2 is part of the HOXA transcription factor cluster
which has an important role in cell differentiation, embry-
onic development and cancer. Recent studies suggest that
HOXA cluster gene expression is under epigenetic con-
trol; it is repressed by epigenetic imprints including 5-
methylcytosines [28]. Similar epigenetic linkage of the
HOXA cluster was observed in hepatic malignancies;
aberrant methylation of HOXA2 CpG islands is often
associated with cholangiocarcinoma [29]. DNA methy-
lation in promoter regions and CG-rich regions is






n = 70 n = 32
Gender—malea 33 (47.1) 20 (62.5) ns
Age (years)a 45.6 ± 13.7 50.28 ± 11.25 ns
Hbe Ag positivea 16 6 ns
Anti Hbe Ab positivea 54 26
HBV DNA (log IU/mL)b 7.4 ± 4.3 7.0 ± 2.5 ns
Serum ALT (IU/L)b 70.5 ± 48.0 83.0 ± 59.87 ns
Serum AST (IU/L)b 45.1 ± 22.5 64.28 ± 47.3 ns
White blood cell count (×109/L)b 6.4 ± 1.5 6.3 ± 1.7 ns
Platelet count (×109/L)b 207.7 ± 45.6 196.5 ± 42.8 ns
Haemoglobin (g/L)b 14.0 ± 1.7 14.5 ± 1.3 ns
Albumin (g/L)b,c 4.4 ± 0.3 4.4 ± 0.3 ns
Prothrombin time (s)b,c 11.4 ± 1.6 11.5 ± 2.5 ns
Conjugated bilirubin (mg/dL)b,c 0.19 ± 0.18 0.26 ± 0.25 ns
Modified histologic activity indexa
0–4 47 (67.1) 1 (3.1) –
5–9 22 (31.4) 25 (78.1) –
10–14 1 (1.4) 5 (15.6) –
15–18 – 1 (3.1) –
Fibrosisa –
0 33 (47.1) – –
1 20 (28.5) – –
2 17 (24.2) – –
3 – 20 (62.5) –
4 – 5 (15.6) –
5 – 5 (15.6) –
6 – 2 (6.2) –
a,bData are shown as number and percentage (a) or mean and standard
deviation (b). The histologic activity index is a sum of portal inflammation,
confluent necrosis, focal lytic necrosis and periportal or periseptal interface
hepatitis scores which was expressed on a scale of 18. Fibrosis stage was
assessed on a scale of 0 to 6
cInformation on conjugated bilirubin, prothrombin time and albumin was
missing in six, two, and five patients, respectively
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Fig. 3 Plots were demonstrated as the correlation between the CpG methylation and severity of the liver disease. The analysis compares hepatic
DNA methylation level in F0-2 with F3-6 according to Ishak staging. Horizontal bars represent the means and 95 % confidence interval. Higher
hepatic HDAC4 (a, b) and HOXA2 (c) methylation and lower PPP1R18 (d) methylation indicates advanced necroinflammation and fibrosis
Fig. 4 Hepatic DNA methylation levels from initial biopsies of non-progressors (no increase in stage of fibrosis) and progressors (≥1 stage increase
in severity of fibrosis). Boxes and bars represent the means and standard error, respectively. Cytosine methylation at HDAC4 (a, b), HOXA2 (c) and
PPP1R18 (d) genes did not differ significantly between the two groups
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frequently associated with gene silencing; since we ob-
tained hypermethylation of the HOXA2 locus within 1500
base pairs of the transcription start site in the current
study, this may lead to repression of the HOXA2 gene in
advanced liver disease. Future studies will be needed to
characterize a comprehensive function for HOXA2 in
viral-hepatitis-related liver disease. The PPP1R18 gene
(also referred as KIAA1949) encodes a phostensin protein
which is localized closely with cytoskeletal proteins such
as actin filaments. Phostensin is mainly expressed in lym-
phocytes, monocytes and macrophages and shown in
many tissues, but higher expression is detected in the
spleen and other lymphatic tissues [30, 31]. Since lower
methylation levels were obtained in the first exon of the
PPP1R18 gene, it is likely that phostensin is up-regulated
around inflammatory and fibrotic milieu in correlation
with disease severity.
Epigenetic modifications can be dynamically regulated,
both in development and disease. In this study, we were
not able to determine if the observed epigenetic differ-
ences are the cause or the consequence of the disease
process. It is likely that our observed patterns of methyla-
tion, particularly in CpG-rich gene regulatory regions, can
modulate inflammatory and fibrogenic pathways; equally,
epigenetic marks could have been acquired subsequently
as an outcome of advanced disease. Moreover, contribu-
tion of heritable epigenetic factors to liver fibrogenesis has
recently been described; therefore, it is also possible that
epigenetic signatures can be inherited across generations
and modify hepatic disease outcome [32, 33]. Data from
the initial biopsies of our follow-up cohort support the
idea that DNA methylation variations may be developed
with disease progression. Indeed, we observed a modest
increase in HOXA2 methylation in progressors compared
to mild reduction in non-progressors. Nevertheless, it is
difficult to reach a definite conclusion due to the limited
sample size.
It is important to note that this epigenetic study was per-
formed using liver needle biopsy samples that contain
several cell types including hepatocytes, myofibroblasts,
endothelial cells, macrophages and other inflammatory
cells. In line with all other epigenetic modifications, it is
likely that some methylated cytosines are cell type-specific,
which can impact on the precision of the epigenome-wide
studies such as this [34]. Another limitation of the study
was the use of moderate sample size in the discovery co-
hort. We aimed to overcome this issue by using a larger
validation cohort to confirm the initial results. Indeed, all
four CpG sites were replicated in the validation cohort. It
is also worth noting that in our study we employed liver
needle biopsy samples, which can represent 1/50,000 of
the whole liver. Sampling variability is therefore another
issue that has previously been observed in the evaluation
of chronic liver disease [35]. We have previously shown
that CpG methylation levels are rather consistent across
the liver; therefore, sampling error appears to be less of a
problem, at least for hepatic DNA methylation [16].
Exploring the epigenetic and cellular basis of chronic liver
disease progression is undoubtedly important. There is a
growing tendency towards the use of epigenetic modifica-
tions as biomarkers of disease in clinical settings. Further-
more, it is also likely that DNA methylation blueprint from
the blood or liver may have utility in diagnosing inflamma-
tory or fibrotic status of the liver [36]. A recently published
study suggests that the PPARγ promoter hypermethylation
in peripheral blood mononuclear cells is associated with se-
vere inflammation and fibrosis in chronic hepatitis B [37].
Our research also suggests that PPARγ promoter hyperme-
thylation of cell-free DNA is a promising biomarker for
non-invasive diagnosis of fibrosis in non-alcoholic fatty
liver disease [38]. Viral hepatitis-induced chronic liver
disease is slowly progressive and a particularly hetero-
geneous clinical condition. Stratification of patients,
and establishment of personalized medicine, needs sig-
nificant improvement which may be overcome by im-
plementation of DNA methylation markers. Moreover,
the highly dynamic nature of epigenetic markers makes
them suitable drug targets. Future therapeutic strategies
may include the modulation of novel genes involved in
inflammation and fibrosis. Further research is required
to broaden the mechanistic role of DNA methylation in
chronic liver disease.
Conclusions
In conclusion, we found novel epigenetic signatures as-
sociated with hepatic inflammation fibrosis in HBV-
related liver disease. These epigenetically modified genes
may be linked with liver disease progression and could
provide further insights into the pathogenesis of chronic
liver disease. Progression-associated CpG sites within
HOXA2, PPP1R18 and HDAC4 genes might have clinical
utility as a prognostic marker of HBV-induced chronic
liver disease.
Methods
A total of 131 patients with chronic HBV infection were
identified and included retrospectively into the study
from a single centre (Katip Çelebi University, Atatürk
Eğitim ve Araştırma Hastanesi, Izmir, Turkey). Patients
were selected based on the medical records with a posi-
tivity for hepatitis B surface antigen (HbsAg) for longer
than 6 months and who have undergone percutaneous
liver biopsy. Patients that received antiviral therapy in
the last 6 months, presence of hepatitis delta infection,
hepatitis C infection, non-alcoholic fatty liver disease,
drug-induced liver injury, autoimmune liver disease, her-
editary hemochromatosis, α1-antitrypsin deficiency or
an average alcohol consumption of over 20 g daily for
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men and over 10 g for women were excluded from the
study. Patients with concomitant human immunodefi-
ciency virus (HIV) infection and/or hepatocellular car-
cinoma were also excluded from the study.
Formalin-fixed paraffin-embedded (FFPE) percutaneous
needle liver biopsy specimens were stained with haema-
toxylin and eosin and picrosirius red/Masson’s trichrome
(data not shown). Hepatic inflammatory activity and the fi-
brosis stage were assessed according to the Ishak system by
expert pathologists [39]. The following demographic and
clinical laboratory parameters were obtained from medical
records: age, sex, aspartate aminotransferase, alanine ami-
notransferase, conjugated bilirubin, albumin, prothrombin
time, complete blood count, HbeAg, anti-Hbe Ab and cir-
culating HBV DNA levels. Genomic DNA was extracted
from FFPE needle biopsy samples by QIAamp DNA micro-
kit (Qiagen) and QIA DNA FFPE tissue kit (Qiagen) as rec-
ommended by the manufacturer and stored at −80 °C.
DNA quality and quantity was assessed by Nanodrop 1000
(Thermo Scientific). DNA samples were hybridized on the
Infinium 450K BeadChip (Illumina, San Diego, USA) to
evaluate genome-wide DNA methylation. 1 μg DNA was
used for bisulfite conversion and repaired by Infinium HD
FFPE restore kit (Illumina, San Diego, USA). Amplification
and hybridization of samples were performed according to
the manufacturer’s protocol. Infinium HumanMethyla-
tion450 BeadChip platform data was analysed and
processed using Bioconductor minfi package (www.biocon-
ductor.org) [40]. It employs Storey FDR correction [41]
where differentially methylated regions are detected using
a permutation test, which means the P values returned are
inherently robust to false discovery. Additionally, during
analysis, we used 10,000 permutations, which give a very
robust answer, given that the standard default for such
analysis is 1000. CpG methylation values for each of the
samples were obtained as β values. Quality control was
implemented, and any β scores with a P value greater than
0.05 in 12.5 % of the samples were excluded. For correc-
tion of systematic differences between type I and type II
probes, subset-quantile within array normalization
(SWAN) was performed. Probes targeting single nucleo-
tide polymorphisms and probes on sex chromosomes
were removed from the downstream analysis. One speci-
men from a severe group was excluded from further
analysis due to failing to provide optimal scores in quality
checks. Bump hunter was used to detect differentially
methylated regions and Bioconductor minfi package was
employed to identify differentially methylated loci [42, 43].
A P value was calculated for the probes, and P value over
0.05 was considered as not significant.
Validation of genome-wide methylation analysis was
performed by bisulfite modification and quantitative pyro-
sequencing. DNA methylation values from HumanMethy-
lation450 BeadChip array probes were compared with the
data obtained from conventional quantitative pyrosequenc-
ing. For validation and verification experiments, bisulfite
conversion of 1 μg DNA was performed by EZ DNA
Methylation GoldTM kit (Zymo Research, Cambridge Bio-
science, UK). The conversion protocol was performed as
follows: 98 °C for 10 min, 64 °C for 2.5 h and 4 °C holding
step. Bisulfite-treated DNA was transferred to spin col-
umns, desulphonated and eluted. Bisulfite-modified DNA
was amplified by PCR with the assays and primers designed
in our laboratory using Pyromark Assay Design Software
SW2.0 (Qiagen, Mainz, Germany). PCR reaction was car-
ried out using 12.5 μL Hot star Taq Master Mix (Qiagen),
5–8 pmol of forward and reverse primers (one of each pri-
mer sets were biotin-labelled) in a 25-μL volume. Forward,





AAAT for HOXA2; and GGGTGGTGGTAGGAATTAAT
AAGA, CAACCTCTCCAACCACAATTAATA, GGGATT
TTTTGGTAAGGTA for PPP1R18.
Amplification was performed according to the following
protocol: 95 °C for 15 min, 50 cycles of 95 °C for 15 s, an-
nealing temperature of 55–60 °C for 30 s, 72 °C for 15 s,
followed by 72 °C for 5 min. Biotin-labelled PCR products
were captured by Streptavidin Sepharose beads (GE Health-
care, UK) and converted to single-stranded DNA by Vac-
uum Prep Tool (Qiagen). Sequencing primers were used to
anneal single-stranded PCR product at 80 °C for 2 min.
Pyrosequencing was performed using Pyromark 96 MD
system (Qiagen), and CpG methylation at each site was
analysed by Pyro Q CG software (Qiagen). Mean methyla-
tion levels from four assays and methylation array were
considered as concordant as absolute methylation differ-
ences were less than 10 %.
Immunohistochemistry for histone deacetylase 4 was per-
formed on FFPE sections. Slides were dewaxed, rehydrated
with alcohol and hydrogen peroxide was used to block en-
dogenous peroxidase activity. Antigen retrieval was per-
formed using citrate buffer (15-M103, Bio-Optica, Italy) in
a microwave for 15 min. Sections were incubated with pri-
mary antibody (anti-HDAC4 ab184983, Abcam) at 37 °C
for 2 h. Slides were washed in TBS-T and incubated with
secondary antibody (biotinylated goat anti-polyvalent).
After TBS-T washing, sections were incubated with
streptavidin biotin peroxidase at room temperature for
10 min. HDAC positivity was shown by diaminobenzi-
dine tetrahydrochloride (DAB). Slides were counter-
stained by haematoxylin.
Statistical analysis
Statistical analysis and graph construction were per-
formed using SPSS software (IBM, USA) and GraphPad
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Prism Software (GraphPad, version 6.0). Results are shown
as the mean value ± confidence interval graphically. Means
were compared via nonparametric tests (Mann-Whitney
U) to define differences for not normally distributed data.
Pearson’s chi-square tests or Fisher’s exact test was used
for categorical variables. A P value of less than 0.05 was
considered statistically significant.
The study was performed in accordance to the Confer-
ence on Harmonization Guidelines for Good Clinical Prac-
tice and ethical guidelines of the Declaration of Helsinki.
Ethical approval for the study protocol was granted by the
Institutional Ethical Committee and Review Board (Atatürk
Eğitim ve Araştırma Hastanesi, Izmir).
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Additional file 1: Figure S1. Flow chart demonstrating patients who
underwent liver biopsy procedure and included into the study.
(DOCX 43 kb)
Additional file 2: Table S1. Summary of differentially methylated
regions. (DOCX 16 kb)
Additional file 3: Table S2. Hypermethylated probes in severe
inflammation and fibrosis. (DOCX 18 kb)
Additional file 4: Table S3. Hypomethylated probes in severe
inflammation and fibrosis. (DOCX 16 kb)
Additional file 5: Figure S2. Validation of the bisulfite modification and
pyrosequencing assays for relevant loci in HDAC4, HOXA2 and PPP1R18
genes. Plots comparing 0, 25, 50, 75 and 100 % of methylated DNA with
obtained methylation results are shown; only assays with an acceptable
performance (r2 values over 0.95) were used in this study. (TIF 149 kb)
Additional file 6: Figure S3. Histone deacetylase 4 immunohistochemistry
in mild and severe disease: HDAC4 is highly expressed in advanced
inflammation and fibrosis. Representative ×200 pictures of HDAC4
immunohistochemistry from five mild (fibrosis stage ≤1) and five severe
(fibrosis stage ≥4) chronic liver disease due to hepatitis B infection.
DAB-positive staining pattern was detected in myofibroblasts, inflammatory
cells and hepatocytes in or near to fibrosis tracts. (TIF 1747 kb)
Additional file 7: Table S4. Demographic, clinical and laboratory
characteristics of the non-progressors and progressors in serial biopsies.
(DOCX 18 kb)
Additional file 8: Figure S4. Change in hepatic DNA methylation levels
between follow-up and initial biopsies of non-progressors (no increase in
stage of fibrosis) and progressors (≥1 stage increase in severity of fibrosis).
Boxes and bars represent the means and standard error of cytosine
methylation at HDAC4 (a, b), HOXA2 (c) and PPP1R18 (d) genes.
(TIF 4146 kb)
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